SCHEMBL124061

SCHEMBL124061

N#Cc1ccc2c(c1)nc(Cl)c1nccn12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 2/20 0.51
GLA P06280 1/20 0.51
GAA P10253 1/20 0.51
CYP11B2 P19099 1/20 0.39
CDC7 O00311 6/20 0.38
HTR3E A5X5Y0 1/20 0.38
HTR3B O95264 1/20 0.38
HTR3A P46098 1/20 0.38
HTR3D Q70Z44 1/20 0.38
HTR3C Q8WXA8 1/20 0.38
KDM1A O60341 2/20 0.36
CDK2 P24941 3/20 0.36
MAP3K14 Q99558 1/20 0.35
HRH4 Q9H3N8 1/20 0.35
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRG2 P18507 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3496046 0.78 HTR3E (0.40) KDM4EALDH1A1HTR3EHTR3BHTR3A
SCHEMBL3789425 0.77 KDM4E (0.61) KDM4EALDH1A1GLAGAACYP11B2
SCHEMBL8279650 0.76 HTR3E (0.38) KDM4EALDH1A1HTR3EHTR3BHTR3A
SCHEMBL29892974 0.75 KDM4E (0.45) KDM4EALDH1A1GLAGAACYP11B2
SCHEMBL31377522 0.75 MAPK8 (0.40) KDM4EALDH1A1HTR3EHTR3BHTR3A
SCHEMBL18584266 0.75 RAD51 (0.44) KDM4EALDH1A1HTR3EHTR3BHTR3A
SCHEMBL3498276 0.75 KDM4E (0.42) KDM4EALDH1A1HTR3EHTR3BHTR3A
SCHEMBL30578099 0.74 MAPK8 (0.54) KDM4EALDH1A1GLAGAAHTR3E
SCHEMBL8118650 0.74 GRIN2D (0.49) KDM4EALDH1A1GLAGAAHTR3E
SCHEMBL120846 0.74 MAPK8 (0.54) KDM4EALDH1A1GLAGAAHTR3E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424537-B1 SUBSTITUTED IMIDAZOQUINOXALINES BAYER IP GMBH (DE) 2015-07-08 EP disclosed
EP-2424537-B1 SUBSTITUTED IMIDAZOQUINOXALINES BAYER IP GMBH (DE) 2015-07-08 EP disclosed
US-8729082-B2 Substituted imidazoquinoxalines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-05-20 US disclosed
US-8729082-B2 Substituted imidazoquinoxalines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-05-20 US disclosed
US-20120128662-A1 SUBSTITUTED IMIDAZOQUINOXALINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-05-24 US disclosed
US-20120128662-A1 SUBSTITUTED IMIDAZOQUINOXALINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-05-24 US disclosed
EP-2424537-A1 SUBSTITUTED IMIDAZOQUINOXALINES Bayer Pharma Aktiengesellschaft (DE) 2012-03-07 EP disclosed
WO-2010124826-A1 SUBSTITUTED IMIDAZOQUINOXALINES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-11-04 WO disclosed
WO-2010124826-A1 SUBSTITUTED IMIDAZOQUINOXALINES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120128662-A1 SUBSTITUTED IMIDAZOQUINOXALINES TTBK1, TTK, TTBK2 KDM4E 4230/4885ALDH1A1 3937/4885GLA 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.